Akums Drugs & Pharmaceuticals Ltd Stock Price Today (NSE: AKUMS)
Fundamental Score
Akums Drugs & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Akums Drugs & Pharmaceuticals Ltd share price today is ₹697.45, up +5.27% on NSE/BSE as of 7 August 2026. Akums Drugs & Pharmaceuticals Ltd (AKUMS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.89K (Cr). The 52-week high for AKUMS share price is ₹714.70 and the 52-week low is ₹409.30. At a P/E ratio of 40.55x, AKUMS is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 8.45% and a debt-to-equity ratio of 0.05.
Akums Drugs & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Akums Drugs & Pharmaceuticals Ltd share price chart: 4.86% return over the past month. 52-week high ₹714.70, 52-week low ₹409.30.
Akums Drugs & Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹672.00 | ₹703.00 | ₹665.85 | ₹697.45 | 6.36L (Cr) | |
| ₹670.00 | ₹670.95 | ₹656.50 | ₹662.55 | 99.69K (Cr) | |
| ₹667.95 | ₹674.70 | ₹661.20 | ₹666.10 | 71.53K (Cr) | |
| ₹680.00 | ₹681.20 | ₹665.10 | ₹667.40 | 82.50K (Cr) | |
| ₹666.70 | ₹688.30 | ₹664.65 | ₹681.20 | 1.44L (Cr) | |
| ₹661.90 | ₹663.90 | ₹653.60 | ₹658.35 | 82.45K (Cr) | |
| ₹662.50 | ₹667.55 | ₹658.00 | ₹660.60 | 1.62L (Cr) | |
| ₹662.00 | ₹668.30 | ₹656.75 | ₹664.55 | 1.49L (Cr) | |
| ₹676.65 | ₹678.80 | ₹657.10 | ₹662.15 | 1.22L (Cr) | |
| ₹687.40 | ₹703.00 | ₹673.70 | ₹675.60 | 1.79L (Cr) |
Akums Drugs & Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹666.70 | ₹703.00 | ₹656.50 | ₹697.45 | +4.61% | |
| ₹623.27 | ₹714.70 | ₹620.00 | ₹658.35 | +5.63% | |
| ₹524.50 | ₹639.84 | ₹517.00 | ₹620.19 | +18.24% | |
| ₹550.00 | ₹567.00 | ₹500.05 | ₹524.50 | -4.64% | |
| ₹473.90 | ₹557.00 | ₹473.90 | ₹547.30 | +15.49% | |
| ₹472.00 | ₹515.00 | ₹456.55 | ₹466.10 | -1.25% | |
| ₹445.00 | ₹506.00 | ₹424.20 | ₹488.15 | +9.70% | |
| ₹453.40 | ₹458.00 | ₹409.30 | ₹439.55 | -3.05% | |
| ₹425.95 | ₹480.50 | ₹414.00 | ₹453.40 | +6.44% | |
| ₹463.95 | ₹481.70 | ₹411.40 | ₹425.95 | -8.19% | |
| ₹441.50 | ₹473.45 | ₹437.00 | ₹460.75 | +4.36% | |
| ₹456.00 | ₹484.00 | ₹438.05 | ₹441.45 | -3.19% |
AI Research Briefing
Powered by Gemini · 2026-04-17
CDMO play with EU optionality; execution is everything.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Akums Drugs shows bullish momentum with positive daily moving averages. 84% increase from the previous close. ICICI Securities upgraded the stock to 'Hold' on April 10, 2026. FII holding increased to 1.38% in March 2026 from 1.14% in December 2025. Akums closed its trading window on April 1, 2026, in anticipation of FY26 results.
CORE STORY (THE REAL GAME)
Akums is being priced as a CDMO play, leveraging its manufacturing capabilities for regulated markets. The key is its ability to secure and execute long-term contracts with global pharma companies, shifting from generics to higher-margin formulations.
- Bullish technical indicators signal upward price momentum
- FIIs increased stake in Q4 FY26
- EU GMP certifications received, paving the way for regulated market access
- New CDMO contract wins
- Successful commencement of European supplies in FY28
- Faster-than-expected ramp-up of Zambia JV
- Small-cap, inherent liquidity risk
- Q2 PAT decline raises concerns about CDMO growth sustainability
- Revenue concentration risk from reliance on large contracts
FII increased stake from 1.14% to 1.38% in Q4 FY26
Indian pharma sector shifting towards backward integration and innovation.
Akums has a ₹1,760 Cr contract with a European pharma company for oral liquid formulations, with commercial supply expected from 2027.
Profit converting to cash. Free Cash Flow 5Y: ₹132.48 Cr
Focus on executing existing contracts and securing new ones in regulated markets. European expansion is key to margin expansion over the next 2-3 years.
Primary Thesis Risk
Failure to execute on EU expansion will decimate the multiple.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Akums Drugs & Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Akums Drugs & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AKUMS across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Profit Growth Track Record (15.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.05)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (5.27x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1037.88 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (8.45%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 40.55x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-39.44%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-55.67% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Akums Drugs & Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Akums Drugs & Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
41.9/100 | ₹697.45₹697 | ₹10891.65₹10891.65 | 40.55Average 40.5 Average | 8.45%Poor 8.45% Poor | 14.94%Average 14.94% Average | 0.05Excellent 0.1 Excellent | 15.68%Excellent 15.68% Excellent | 9.87%Good 9.87% Good | 0.14% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Akums Drugs & Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for AKUMS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹22.60 | ₹453.40 | 20.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Akums Drugs & Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for AKUMS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
9.69%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-39.44%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.87%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
15.68%
Compounded annual net profit growth over 5 years
Akums Drugs & Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AKUMS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Akums Drugs & Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Akums Drugs & Pharmaceuticals Ltd (AKUMS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Akums Drugs & Pharmaceuticals Ltd
About AKUMS (Akums Drugs & Pharmaceuticals Ltd)
Akums Drugs & Pharmaceuticals Ltd. is a powerhouse within the Indian pharmaceutical landscape, standing as a comprehensive contract development and manufacturing organization (CDMO...). They function as a vital hub, orchestrating the production of a vast portfolio of pharmaceutical and healthcare solutions, spanning from essential medications to sophisticated formulations. The company's expertise extends across diverse therapeutic areas, catering to both acute and chronic conditions with unwavering commitment to quality and innovation. With a strong foothold in the domestic market, Akums also strategically projects its reach globally, solidifying its position as a reliable partner for pharmaceutical companies seeking manufacturing excellence. This unwavering dedication has positioned Akums as a significant contributor to the healthcare industry, enabling the provision of affordable and quality healthcare solutions for diverse demographics. Beyond conventional pharmaceuticals, Akums embraces a holistic approach to well-being, demonstrated by its involvement in the production of ayurvedic medicines, herbal remedies, and nutraceuticals. This reflects an awareness of the growing consumer demand for natural and alternative therapies, with production conducted under rigorous regulatory standards and quality controls. The company's comprehensive product range further incorporates toiletries, derma and cosmetic products, and food supplements, showcasing its diversification and commitment to addressing various aspects of health and personal care. Akums is dedicated to continuously refining its processes and technologies, ensuring the delivery of products that align with the evolving needs of the healthcare industry. Akums Drugs & Pharmaceuticals Ltd. operates a network of state-of-the-art manufacturing facilities adhering to stringent international quality standards, including certifications from WHO-GMP and other reputed regulatory bodies. This infrastructural strength enables the company to deliver a wide range of dosage forms, including tablets, capsules, liquids, injectables, and topical preparations. Moreover, the company offers a comprehensive suite of services encompassing formulation development, analytical testing, and stability studies, positioning it as a complete solution provider for pharmaceutical companies. By fostering collaborations and partnerships, Akums aims to drive advancements in healthcare, enabling access to quality and affordable medicines for populations worldwide.
Company Details
Key Leadership
Latest News
AKUMS Share Price: Frequently Asked Questions
What is the current share price of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd (AKUMS) trades at ₹697.45 on NSE and BSE. Market cap ₹10.89K (Cr). Educational data only.
What is the P/E ratio of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has a P/E of 40.55x vs industry average 34.89x.
What is the Bull Run score for Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has a Bull Run score of 41.9/100 based on 25+ financial parameters.
Does Akums Drugs & Pharmaceuticals Ltd pay dividends?
Akums Drugs & Pharmaceuticals Ltd has a dividend yield of 0.14%. Past dividends don't guarantee future payments.
What is the ROE of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has ROE of 8.45%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has debt-to-equity of 0.05.
Is Akums Drugs & Pharmaceuticals Ltd a good investment?
Bull Run gives Akums Drugs & Pharmaceuticals Ltd a score of 41.9/100. This is not investment advice — consult a SEBI-registered advisor.